# Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

> **NCT00095563** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- High-grade Salivary Gland Carcinoma
- High-grade Salivary Gland Mucoepidermoid Carcinoma
- Low-grade Salivary Gland Carcinoma
- Low-grade Salivary Gland Mucoepidermoid Carcinoma
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Recurrent Salivary Gland Cancer
- Salivary Gland Acinic Cell Tumor
- Salivary Gland Adenocarcinoma
- Salivary Gland Adenoid Cystic Carcinoma
- Salivary Gland Malignant Mixed Cell Type Tumor

## Interventions

- **DRUG:** lapatinib ditosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00095563
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2009-02
- **Final completion:** 2009-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095563, "Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00095563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*